BETA-O/S/N FATTY ACID BASED COMPOUNDS AS ANTIBACTERIAL AND ANTIPROTOZOAL AGENTS

摘要

The present invention relates to beta-O/S/N fatty acids and derivatives thereof, in particular the compounds of formula (I) as described and defined herein, and their pharmaceutical use, including their use in the treatment or prevention of bacterial as well as protozoan infections, in particular the treatment or prevention of infections with Gram-positive and/or Gram-negative bacteria and infectious diseases caused by and/or related to Gram-positive and/or Gram-negative bacteria. The invention further relates to the use of these compounds for preventing or eliminating biofilms.;

主权项

1. A compound of formula (I) wherein:
X is selected from —CO—NH2, —COOH, —CH2—OH, —CO—NH(C1-4 alkyl), —CO—N(C1-4 alkyl)(C1-4 alkyl), —CO—SH, —CH2—SH, —CH2—NH2, —CH2—NH(C1-4 alkyl), —CO—O(C1-6 alkyl), —CO—O(C2-6 alkenyl), —CO—O(C2-6 alkynyl), —CO—O(aryl), —CO—O(heteroaryl), —CO—S(C1-6 alkyl), —CO—S(C2-6 alkenyl), —CO—S(C2-6 alkynyl), —CO—S(aryl), or —CO—S(heteroaryl);Y is selected from —OH, —O—CO—(C1-6 alkyl), —O(C1-6 alkyl), —O(C2-6 alkenyl), —O(C2-6 alkynyl), —O—CO—(C2-6 alkenyl), —O—CO—(C2-6 alkynyl), —O(aryl), —S(heteroaryl), —SH, —S(C1-6 alkyl), —S(C2-6 alkenyl), —S(C2-6 alkynyl), —S—CO—(C1-6 alkyl), —S—CO—(C2-6 alkenyl), —S—CO—(C2-6 alkynyl), —S(aryl), —S(heteroaryl), —NH2, —NH(C1-6 alkyl), —N(C1-6 alkyl)(C1-6 alkyl), —NH—CO—(C1-6 alkyl), or —N(C1-6 alkyl)-CO—(C1-6 alkyl),R1 and R3 are each independently selected from C2-12 alkenyl, —(C1-12 alkylene)-aryl, C1-12 alkyl, C2-12 alkynyl, aryl, heteroaryl, —(C2-12 alkenylene)-aryl, —(C2-12 alkynylene)-aryl, —(C1-12 alkylene)-heteroaryl, —(C2-12 alkenylene)-heteroaryl, —(C2-12 alkynylene)-heteroaryl, a polyethylene glycol moiety, or C3-12 alkyl in which at least one and up to one third of the C atoms are in each case substituted by an atom or a moiety independently selected from —O—, —S—, —NH—, —SO—, or —SO2—, wherein said C1-12 alkyl, said C2-12 alkenyl, said C2-12 alkynyl, said aryl, said heteroaryl, said —(C1-12 alkylene)-aryl, said —(C2-12 alkenylene)-aryl, said —(C2-12 alkynylene)-aryl, said —(C1-12 alkylene)-heteroaryl, said —(C2-12 alkenylene)-heteroaryl, said —(C2-12 alkynylene)-heteroaryl, said polyethylene glycol moiety, or said C3-12 alkyl is optionally substituted with one or more groups independently selected from halogen, —CN, —CF3, —CN2CF3, benzoyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, —OH, —O(C1-6 alkyl), —SH, —S(C1-6 alkyl), —NH2, —NH(C1-6 alkyl), —N(C1-6 alkyl)(C1-6 alkyl), —CO—(C1-6 alkyl), —CO—NH2, —CO—NH(C1-6 alkyl), —CO—N(C1-6 alkyl)(C1-6 alkyl), heteroaryl, polyethylene glycol moiety, alkylene-polyethylene glycol moiety or polyethylene glycol-alkyl moiety, wherein at least one of R1 and R3 is said —(C1-12 alkylene)-aryl, said aryl, said heteroaryl, said —(C2-12 alkenylene)-aryl, said —(C2-12 alkynylene)-aryl, said —(C1-12 alkylene)-heteroaryl, said —(C2-12 alkenylene)-heteroaryl, or said —(C2-12 alkynylene)-heteroaryl or comprises at least 4 consecutively arranged C-atoms that are covalently linked together if X is —CH2—OH; andR2 and R4 are each —H; or a pharmaceutically acceptable salt, solvate or prodrug thereof for use as a medicament.